Rallybio(RLYB)의 주가가 Horizon Therapeutics로부터 5천만 달러의 계약 종료 수수료를 지급받았다는 소식에 크게 상승했습니다. Horizon Therapeutics는 Rallybio의 희귀 혈액 질환 치료제 개발을 지원하기 위해 2021년 7월 파트너십을 체결했지만, 결국 계약을 종료하고 해당 금액을 지불하게 되었습니다. Horizon Therapeutics는 이 계약 종료로 인해 Rallybio의 프로그램에 대한 권리를 확보하지 못했습니다. 이번 수수료 지급은 Rallybio에게 즉각적인 재정적 혜택을 제공하며, 향후 연구 개발에 긍정적인 영향을 미칠 것으로 예상됩니다.
🌐 English Briefing
Rallybio (RLYB) stock experienced a significant surge following the announcement that it received a $50 million termination fee from Horizon Therapeutics. The fee was incurred as Horizon Therapeutics ended their agreement with Rallybio. Horizon Therapeutics had initially entered into a partnership in July 2021 to support Rallybio's development of therapies for rare blood disorders. However, Horizon Therapeutics did not acquire rights to Rallybio's programs as a result of this termination. The payment provides Rallybio with immediate financial benefits and is expected to positively impact its future research and development efforts.
Auto-translated by AI for international readers.
원문 (English)
Rallybio stock surges after receiving $50M termination fee